Brought to you by 
Bayer Forms Endometriosis Collaboration with Evotec; Later Expanded to other Indications; BAY1817080 Discontinued
22 Mar 2022
Executive Summary
For the next five years, Bayer HealthCare Pharmaceuticals AG and drug discovery firm Evotec AG have agreed to identify three candidates against multiple targets--selected by both companies--for endometriosis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer Forms Endometriosis Collaboration with Evotec; Later Expanded to other Indications; BAY1817080 Discontinued
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice